mbx-2044
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2006 (NCT00422487)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
PPARG modulator
Selective PPAR gamma modulator (SPPAR?M)
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545020 ↗
Also known as
- mbx-2044
- mbx-2044
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00422487 | Phase 2 | Oct 1, 2006 | CymaBay Therapeutics, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CymaBay Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2006 |
1 organizations
Page 1 / 1